Alaunos Therapeutics
TCRT
156 hedge funds and large institutions have $281M invested in Alaunos Therapeutics in 2020 Q4 according to their latest regulatory filings, with 27 funds opening new positions, 40 increasing their positions, 53 reducing their positions, and 25 closing their positions.
1% more funds holding
Funds holding: 154 → 156 (+2)
8% more call options, than puts
Call options by funds: $2.72M | Put options by funds: $2.51M
8% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 25
4% more capital invested
Capital invested by funds: $270M → $281M (+$11.5M)
0.01% more ownership
Funds ownership: 0.34% → 0.35% (+0.01%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
25% less repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 53
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$9.48M |
| 2 |
DCM
Discovery Capital Management
South Norwalk,
Connecticut
|
+$4.2M |
| 3 |
JP Morgan Chase
New York
|
+$2.09M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.82M |
| 5 |
Two Sigma Advisers
New York
|
+$1.04M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$4.18M |
| 2 |
SG Americas Securities
New York
|
-$1.89M |
| 3 |
State Street
Boston,
Massachusetts
|
-$1.78M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$838K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$688K |
TCRT Hedge Fund Activity: Q4 2020 in Review
156 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Alaunos Therapeutics (TCRT) for Q4 2020, worth a combined $281M — up 4.3% from $270M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new TCRT positions and 25 closed out — a net gain of 2 holders — while 40 added to existing stakes and 53 trimmed.
The largest buyer was BlackRock, adding an estimated $9.48M. The largest seller was Goldman Sachs, cutting an estimated $4.18M.
- 156 institutional investors held Alaunos Therapeutics (TCRT) as of Q4 2020, up from 154 in Q3 2020.
- Funds reported $281M of Alaunos Therapeutics stock for Q4 2020, up 4.3% quarter-over-quarter.
- 27 funds opened new Alaunos Therapeutics positions in Q4 2020 and 25 closed out, a net change of +2 holders.
- The largest Alaunos Therapeutics buyer in Q4 2020 was BlackRock, an estimated $9.48M added.
- The largest Alaunos Therapeutics seller in Q4 2020 was Goldman Sachs, an estimated $4.18M sold.
Based on aggregated 13F filings for Q4 2020.